Author

Priya Bains

Observed name: P. Bains

Institution: University of British Columbia

Observed institutions: University of British Columbia, Lions Gate Hospital

ORCID: 0009-0007-7053-5691

Observed ORCID: 0009-0007-7053-5691

OpenAlex ID: A5047796657

1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)

2023 · D.A. Breadner, G. Liu, et al. · Annals of Oncology · 3

Exploring the student perspective on the implementation and impact of patient voice in an entry to practice doctor of pharmacy program

2026 · Priya Bains, Karen Dahri · Currents in Pharmacy Teaching and Learning

MA08.07 OCELOT: A Pan-Canadian Study of Osimertinib for Patients with Treatment Naive Advanced NSCLC with Uncommon EGFR Mutations

2025 · D. Breadner, G. Liu, et al. · Journal of Thoracic Oncology

British Columbia community pharmacy during COVID-19: Describing the patient experience via Google reviews

2024 · Priya Bains, Fong Chan, et al. · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada

P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study

2024 · S. Verma, M.D. Vincent, et al. · Journal of Thoracic Oncology

EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L

2022 · D. Breadner, G. Liu, et al. · Journal of Thoracic Oncology

Works count: 6

Citation count: 3

H-index: 1

I10-index: